Exhibit 99.1



March 10, 2017

Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline

LEXINGTON, MA — Pulmatrix, Inc. (NASDAQ: PULM) today announces 2016 financial results, reviews the Company’s recent progress, and provides an outlook for 2017 for its pulmonary disease development pipeline.

“The Company continues to advance its two iSPERSE-based product candidates and recently strengthened our balance sheet, with the closing of two registered direct offerings that brought in net proceeds of approximately $7.5 million,” said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. “We expect pre-clinical data in the first half of 2017 on PUR1900 targeting fungal infections for severe asthma and cystic fibrosis patients and seek to secure a strategic partner(s) on PUR0200, a branded generic bronchodilator for COPD. As our product pipeline and iSPERSE technology continue to advance, we feel the Company is positioned for success as a leader in the treatment of Respiratory diseases.”

Planned 2017 Milestones

Pulmatrix plans to continue advancement of our active pipeline in 2017: Following on our 2016 successful clinical trial in the EU for PUR0200, a branded generic bronchodilator for COPD, the company is planning meetings with both EU and US Regulators regarding the critical path for clinical development to approval and plans to continue development towards initial clinical testing in patients of PUR1900, an inhaled anti-fungal initially targeted for patients with cystic fibrosis and severe asthma.



    Following up on our successful pharmacokinetic equivalence pilot trial in 2016, Pulmatrix plans to seek scientific advice from three EU countries to gain a better understanding of the pivotal trial design for PUR0200.


    Pulmatrix intends to seek a pre-IND meeting with the FDA to inform the US clinical development path for PUR0200 in the second half of 2017.


    Continue CMC development work in the first half of 2017 to support a future European pivotal pharmacokinetic bioequivalence approval study as well as the US development path.


    Pulmatrix seeks to secure partnership for the rights to PUR0200 in 2017 for a geography or geographies to be determined.



    Complete CMC development work and non-clinical safety testing to support clinical development of PUR1900 for severe asthma and cystic fibrosis.


    Plan a Phase I/IB trial in healthy normal volunteers (HNV) and severe asthma patients including safety/tolerability and pharmacokinetic readout following inhalation of PUR1900.



    Continue pre-clinical development of PUR1500 moving towards lead selection based on either a 505(b)2 or in license opportunity.

2016 and 2017 YTD Progress

In 2016 and early 2017, Pulmatrix achieved several research, clinical and business milestones, reflective of the Company’s progress. These milestones include the following:


    Completed the pilot study of PUR0200 for patients with chronic obstructive pulmonary disease (COPD) and announced positive pharmacokinetic bioavailability data that informed our continued development of PUR0200 for European Registration.


    The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Pulmatrix’s wholly-owned drug candidate PUR1900. PUR1900 combines a previously approved anti-fungal drug with its proprietary dry powder iSPERSETM delivery platform to effectively deliver to the lungs a drug used to treat pulmonary fungal infections in patients with cystic fibrosis (CF).

The following information was filed by Pulmatrix, Inc. (PULM) on Friday, March 10, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Pulmatrix, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pulmatrix, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Log in with your credentials


Forgot your details?

Create Account